These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 35941104)

  • 1. Blocking ActRIIB and restoring appetite reverses cachexia and improves survival in mice with lung cancer.
    Queiroz AL; Dantas E; Ramsamooj S; Murthy A; Ahmed M; Zunica ERM; Liang RJ; Murphy J; Holman CD; Bare CJ; Ghahramani G; Wu Z; Cohen DE; Kirwan JP; Cantley LC; Axelrod CL; Goncalves MD
    Nat Commun; 2022 Aug; 13(1):4633. PubMed ID: 35941104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC.
    Zhang H; Garcia JM
    Expert Opin Pharmacother; 2015 Jun; 16(8):1245-53. PubMed ID: 25945893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome.
    Currow DC; Abernethy AP
    Future Oncol; 2014 Apr; 10(5):789-802. PubMed ID: 24472001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia.
    Currow D; Temel JS; Abernethy A; Milanowski J; Friend J; Fearon KC
    Ann Oncol; 2017 Aug; 28(8):1949-1956. PubMed ID: 28472437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04).
    Katakami N; Uchino J; Yokoyama T; Naito T; Kondo M; Yamada K; Kitajima H; Yoshimori K; Sato K; Saito H; Aoe K; Tsuji T; Takiguchi Y; Takayama K; Komura N; Takiguchi T; Eguchi K
    Cancer; 2018 Feb; 124(3):606-616. PubMed ID: 29205286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index.
    Naito T; Uchino J; Kojima T; Matano Y; Minato K; Tanaka K; Mizukami T; Atagi S; Higashiguchi T; Muro K; Takayama K; Furuse J; Morishima E; Takiguchi T; Tamura K
    Cancer; 2022 May; 128(10):2025-2035. PubMed ID: 35195274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials.
    Temel JS; Abernethy AP; Currow DC; Friend J; Duus EM; Yan Y; Fearon KC
    Lancet Oncol; 2016 Apr; 17(4):519-531. PubMed ID: 26906526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Anamorelin, a Novel Non-Peptide Ghrelin Analogue, in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Cachexia-Review and Expert Opinion.
    Currow DC; Maddocks M; Cella D; Muscaritoli M
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30400622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model.
    Northrup R; Kuroda K; Duus EM; Barnes SR; Cheatham L; Wiley T; Pietra C
    Support Care Cancer; 2013 Sep; 21(9):2409-15. PubMed ID: 23579947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brief versions of the FACIT-fatigue and FAACT subscales for patients with non-small cell lung cancer cachexia.
    Salsman JM; Beaumont JL; Wortman K; Yan Y; Friend J; Cella D
    Support Care Cancer; 2015 May; 23(5):1355-64. PubMed ID: 25351456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacological profile and clinical efficacy of anamorelin HCl (ADLUMIZ
    Nakanishi Y; Higuchi J; Honda N; Komura N
    Nihon Yakurigaku Zasshi; 2021; 156(6):370-381. PubMed ID: 34719572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anamorelin for cancer cachexia.
    Nishie K; Sato S; Hanaoka M
    Drugs Today (Barc); 2022 Mar; 58(3):97-104. PubMed ID: 35274629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emerging role of anamorelin hydrochloride in the management of patients with cancer anorexia-cachexia.
    Currow DC; Skipworth RJ
    Future Oncol; 2017 Aug; 13(20):1767-1783. PubMed ID: 28621564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival.
    Zhou X; Wang JL; Lu J; Song Y; Kwak KS; Jiao Q; Rosenfeld R; Chen Q; Boone T; Simonet WS; Lacey DL; Goldberg AL; Han HQ
    Cell; 2010 Aug; 142(4):531-43. PubMed ID: 20723755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An overview of anamorelin as a treatment option for cancer-associated anorexia and cachexia.
    Fonseca GWPD; von Haehling S
    Expert Opin Pharmacother; 2021 May; 22(7):889-895. PubMed ID: 33491505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ghrelin receptor agonist HM01 mimics the neuronal effects of ghrelin in the arcuate nucleus and attenuates anorexia-cachexia syndrome in tumor-bearing rats.
    Borner T; Loi L; Pietra C; Giuliano C; Lutz TA; Riediger T
    Am J Physiol Regul Integr Comp Physiol; 2016 Jul; 311(1):R89-96. PubMed ID: 27147616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type II receptor inhibition and β-2 agonist.
    Toledo M; Busquets S; Penna F; Zhou X; Marmonti E; Betancourt A; Massa D; López-Soriano FJ; Han HQ; Argilés JM
    Int J Cancer; 2016 Apr; 138(8):2021-9. PubMed ID: 26595367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial.
    Takayama K; Katakami N; Yokoyama T; Atagi S; Yoshimori K; Kagamu H; Saito H; Takiguchi Y; Aoe K; Koyama A; Komura N; Eguchi K
    Support Care Cancer; 2016 Aug; 24(8):3495-505. PubMed ID: 27005463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of anorexia-cachexia syndrome and rational for treatment with selective ghrelin receptor agonist.
    Esposito A; Criscitiello C; Gelao L; Pravettoni G; Locatelli M; Minchella I; Di Leo M; Liuzzi R; Milani A; Massaro M; Curigliano G
    Cancer Treat Rev; 2015 Nov; 41(9):793-7. PubMed ID: 26386985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of Activin.
    Zhong X; Narasimhan A; Silverman LM; Young AR; Shahda S; Liu S; Wan J; Liu Y; Koniaris LG; Zimmers TA
    J Cachexia Sarcopenia Muscle; 2022 Aug; 13(4):2146-2161. PubMed ID: 35510530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.